HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

NOW APPROVED For moderate to severe rheumatoid arthritis (RA) in adult MTX-IR patients1

Older woman in a harnass, ziplining Older woman in a harnass, ziplining Older woman in a harnass, ziplining
The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX

In SELECT-COMPARE, RINVOQ + MTX achieved superiority in its ranked secondary endpoints (ACR50, HAQ-DI, and pain reduction) at Week 12.2

ACR=American College of Rheumatology; HAQ-DI=health assessment questionnaire disability index; IR=intolerance or inadequate response; MTX = methotrexate

Clinical Trial Overview

*P ≤ 0.001 RINVOQ vs Placebo

SELECT-COMPARE (Study RA-IV) Study Design Intro:1,2 
48-week, randomized, double-blind, active comparator-controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at week 12 vs. placebo. Prespecified blinded rescue protocol occurred at weeks 14, 18, 22, or 26.

Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
ACR Response Rates

36
63
71*
15
29
45*†
5
13
25†

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analysis were not controlled for multiplicity; P-values obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

SELECT-COMPARE:
ACR502-4

Treatment groups are by initial randomization. Observations after rescue were handled using NRI (weeks 14-22) and LOCF (week 26).3

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analysis was not controlled for multiplicity; P-value obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

Overview of SELECT-COMPARE, including results of UPADAC + MTX vs HUMIRA (adalimumab) + MTX

 

Dr. Roy Fleischmann, MD, outlines head-to-head superiority data and other key highlights from the trial.

Demonstrated superiority in HAQ-DI at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in HAQ-DI at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in HAQ-DI at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
HAQ-DI2,3,5,7

Treatment groups are by initial randomization (ANCOVA). Observations after rescue treatment switch were imputed as LOCF (weeks 14-26).7

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
Pain Reduction2,3,6,7

Treatment groups are by initial randomization (ANCOVA). Observations after rescue treatment switch were imputed as LOCF (weeks 14-26).7

P≤0.001 RINVOQ + MTX vs Placebo + MTX; Analysis was not controlled for multiplicity; p-value obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

Explore how RINVOQ helped some patients achieve remission, even without MTX

Explore DAS28-CRP<2.6 data at Weeks 12 or 14, along with additional measures

Discover how RINVOQ Complete can provide exceptional access and patient support

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking